Cargando…

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review

Tripple negative breast cancer (TNBC) accounts for approximately 15% of breast cancers. It is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER-2 Over expression. Expression of ER, PR and HER-2 plays an important role in therapeutic assessment of patients with bre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kandula, Mahesh, Ch, Kalyan Kumar, YS, Ammi Raju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649777/ https://www.ncbi.nlm.nih.gov/pubmed/29147345 http://dx.doi.org/10.4021/wjon681e

Ejemplares similares

Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer
por: Tagliaferri, Barbara, et al.
Publicado: (2020)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
por: Kurozumi, Sasagu, et al.
Publicado: (2017)

Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
por: Nishimura, Reiki, et al.
Publicado: (2011)

Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer
por: Dobrescu, Andrei, et al.
Publicado: (2011)

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
por: Torrisi, R, et al.
Publicado: (2008)

S100A9 expressed in ER(−)PgR(−) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival
por: Bergenfelz, Caroline, et al.
Publicado: (2015)

Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study
por: Paleari, Laura, et al.
Publicado: (2020)

Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma
por: Saglam, Ozlen, et al.
Publicado: (2022)

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology
por: Kurbel, Sven, et al.
Publicado: (2017)

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
por: Torrisi, R, et al.
Publicado: (2007)

Association of the PROGINS PgR polymorphism with susceptibility to female reproductive cancer: A meta-analysis of 30 studies
por: Zhou, Chen, et al.
Publicado: (2022)

Association of +331G/A PgR Polymorphism with Susceptibility to Female Reproductive Cancer: Evidence from a Meta-Analysis
por: Chaudhary, Sanjib, et al.
Publicado: (2013)

The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients
por: Dehghani, Mehdi, et al.
Publicado: (2020)

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
por: Kurozumi, Sasagu, et al.
Publicado: (2015)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Apigenin Inhibits Growth of Breast Cancer Cells: The Role of ERα and HER2/neu
por: Scherbakov, A. M., et al.
Publicado: (2015)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
por: Sorbye, Sveinung W, et al.
Publicado: (2013)

Unusual Gastric Metastasis in Triple-Negative (Estrogen Receptor/Progesterone Receptor/HER2neu Negative) GATA-Binding Protein 3-Positive Breast Cancer
por: Baa, Annie Kanchan, et al.
Publicado: (2020)

Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
por: Baumann, Jan, et al.
Publicado: (2016)

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
por: De Giovanni, Carla, et al.
Publicado: (2019)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment
por: Zhou, Yihan
Publicado: (2023)

Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma
por: Ahmed, Hussain Gadelkarim, et al.
Publicado: (2011)

Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study
por: Hussein, Israa A, et al.
Publicado: (2020)

Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure
por: Kmieciak, Maciej, et al.
Publicado: (2011)

Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer
por: Tobias, Joshua, et al.
Publicado: (2022)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
por: Puri, Vandana, et al.
Publicado: (2011)

Comparison of Her2/Neu Oncoprotein in Serum and Tissue Samples in Women with Breast Cancer
por: Pokhrel, Rakesh, et al.
Publicado: (2022)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Compendio informativo PGR : órgano de difusión de la Procuraduría General de la República.
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_1dhhf0el5rakhe776fgvpm59rk